CTC Status May Indicate Effectiveness of Anthracycline-Free
Anthracycline-free chemotherapy may be as effective as anthracycline-containing chemotherapy in patients with HER2-negative, hormone receptor (HR)–positive early breast cancer, according to data from a new study evaluating the presence of circulating tumor cells (CTCs) after adjuvant chemotherapy (Clin Breast Cancer 2017 Jan 9. [Epub ahead of print]).

The investigators performed a translational substudy of the German SUCCESS C trial, a randomized, multicenter, open-label, Phase III clinical trial of 3,642 patients, which evaluated the effect of an anthracycline-free adjuvant chemotherapy regimen in HER2-negative breast cancer and addressed the role of lifestyle intervention in early breast cancer prognosis...